

**Maryland Board of Pharmacy  
Public Board Meeting**

**Agenda**  
**Date: July 19, 2017**

<b>Name</b>	<b>Title</b>	<b>Present</b>	<b>Absent</b>	<b>Present</b>	<b>Absent</b>
<b>Board Committee</b>					
Ashby, D.	Commissioner				
Bouyoukas, E	Commissioner				
Evans, K.	Commissioner				
Gavgani, M. Z.	Commissioner/President				
Hardesty, J.	Commissioner				
Leikach, N.	Commissioner				
Morgan, K.	Commissioner/Treasurer				
Oliver, B	Commissioner				
Peters, R.	Commissioner				
St. Cyr, II, Z. W.	Commissioner/Secretary				
Toney, R.	Commissioner				
Yankellow, E.	Commissioner				
<b>Board Counsel</b>					
Bethman, L.	Board Counsel				
Felter, B.	Staff Attorney				
<b>Board Staff</b>					
Speights-Napata, D.	Executive Director				
Fields, E.	Deputy Director /Operations				
Evans, T.	Pharmacist Inspector				
Page, A.	Executive Administrative Associate				
Brand, E.	Licensing Manager				
Logan, B.	Legislation/Regulations Manager				



Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

C. Licensing	E. Brand, Licensing Manager	1. Unit Updates					
		2. Monthly Statistics					
		License Type	New	Renewed	Reinstated	Total	
		Distributor	33	176	0	1,280	
		Pharmacy	22	0	1	2,112	
		Pharmacist	80	410	0	11,388	
		Vaccination	18	0	0	4,433	
		Pharmacy Intern - Graduates	9	0	0	50	
		Pharmacy Intern - Students	68	18	0	976	
		Pharmacy Technician	119	256	7	9,817	
TOTAL	349	860	8	30,056			
D. Compliance	T. Evans, Pharmacist Inspector	1. Unit Updates					
2. Monthly Statistics							

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<b>Complaints &amp; Investigations:</b>  New Complaints – 27 Resolved (Including Carryover) –55 Actions within Goal – 44/55 Final disciplinary actions taken – 10 Summary Actions Taken – 2 Average days to complete – 0	
<b>E. Legislation &amp; Regulations</b>	<b>B. Logan, Legislation and Regulations Manager</b>	<u><b>1. COMAR 10.34.02.03 D Proof of Proficiency in English</b></u>  <u><b>2. COMAR 10.34.37 Pharmacy Permit Holder Requirements — Wholesale Distribution and Non-Resident Pharmacy Operations</b></u>  <u><b>3. COMAR 10.34.05.05 Security Responsibility.</b></u>  <u><b>4. COMAR 10.34.34.05 Pharmacy Students.</b></u>  <u><b>5. COMAR 10.34.40 Pharmacist Administration of Self-Administered Drugs</b></u>	
<b>III. Committee Reports</b> <b>A. Practice Committee</b>	<b>R. Peters, Chair</b>	<u><b>1. Contraceptives in Vending Machines</b></u>  <u><b>2. Jeff Kunkel</b></u> In order to be part of the solution to the opioid epidemic, our hospital and our outpatient pharmacy are looking to take proactive steps to help place Narcan (the agent used to reverse the effects of opioids) into the hands of patients and caregivers in need in response to the new standing order placed on 06/01/17 by Dr. Howard Haft. I would like to explain a process and determine if this is within the scope of MD Pharmacy Law.  Our outpatient pharmacy would like to package Narcan Kits (containing Narcan, 2 CPR shields, and rubber gloves) and label	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<p>the product with a label with all necessary label requirements except patient name, RX #, expiration date, and date filled. Our pharmacy would place this product into our emergency room automated dispensing device (PYXIS) as we are an Ambulatory Care pharmacy within an acute care hospital. When a patient presented to the emergency room (after our pharmacy has closed) the emergency room would dispense the Narcan Kit and complete the balance of the label (patient name, RX #, expiration date, and date dispensed.)</p> <p>Upon dispensing (by next day), our Emergency department will provide us a log with (patient name, RX #, expiration date, and date dispensed) and our pharmacy will then enter the “RX” into our pharmacy dispensing system for record keeping purposes and affix the RX#, date, expiration date, and specific patient to the RX.</p> <p>The notables here are we will have a pharmacist either on site in the hospital or on call and available via phone 24/7 when both our inpatient pharmacy and outpatient pharmacy are closed. So it would be feasible to have the product dispensed when no pharmacist was present in the building.</p> <p><b><u>Response:</u></b> The Board reviewed your proposal regarding alternative options to dispensing Narcan when the hospital pharmacy is closed. If the hospital wishes to utilize an automated medication system to dispense naloxone under the auspices of the hospital pharmacy permit, the system must comply with the Board’s automation regulations, COMAR 10.34.28.05. The regulations require, among other things, that a pharmacist reviews each order for medication: (1) after the order has been entered into the system; and (2) before the system permits access to the medication. Alternatively, the attending physician in the emergency room may dispense the Naloxone if the physician has a dispensing permit from the Board of Physicians. The Board</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		recommends that you present this issue to the appropriate committee within your facility to determine the mechanism that will best suit the needs of your patients	
<b>B. Licensing Committee</b>	<b>D. Ashby, Chair</b>	<p><b>1. Review of Pharmacist Applications:</b></p> <p>a) <b>I. Lio-</b> Email request of NAPLEX score transfer extension. She graduated in 2016 and score transferred to MD. She applied to MD as an exam applicant with her NAPLEX score only valid for one year, until June 3, 2017. She is requesting that the Board grant her a NAPLEX score transfer extension for up to four months, until October 3, 2017, to ensure that her application and scores will still be valid when she takes the MPJE exam a second time.  <i>Licensing Committee's Recommendation:</i> Approve</p> <p>b) <b>J. Diala-</b> Request for application expiration date extension. She passed the NAPLEX on March 8, 2017, and had the score transferred to MD. Due to lack of availability, the earliest date she was able to schedule for the MPJE was June 19, 2017. The application expired on June 14, 2017. She is unemployed and, at this time, it would be very difficult for her to pay the application fee again.  <i>Licensing Committee's Recommendation:</i> Deny</p> <p><b>2. Review of Pharmacy Intern Applications: NONE</b></p> <p><b>3. Review of Pharmacy Technician Applications: NONE</b></p> <p><b>4. Review of Distributor Applications: NONE</b></p> <p><b>5. Review of Pharmacy Applications:</b></p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<p>a) <b>Applicant #113198</b>- In 2011, the Florida Department of Health filed a complaint against the pharmacy for purchasing from a Distributor not licensed in Florida. Pharmacy was placed on probation and paid prosecution costs of \$1,874.74. Owner disagrees with the Board's policy that the MD licensed pharmacist must be on site at the pharmacy.  <u>Licensing Committee's Recommendation</u>: Board states that pharmacist has to be readily available at the pharmacy for at least a portion of the time.</p> <p>6. <b>Review of Pharmacy Technicians Training Programs:</b>  a) <b>Brightwood College</b>- Requesting approval as a training program.  <u>Licensing Committee's Recommendation</u>: Approve</p> <p>7. <b>New Business:</b>  a) <b>Vaccination Registration Application</b>- Update to Vaccine application to include training received in Pharmacy school.  <u>Licensing Committee's Recommendation</u>: Approve</p>	
C. Public Relations Committee	E. Yankellow, Chair	Public Relations Committee Update:	
D. Disciplinary	K. Morgan, Chair	Disciplinary Committee Update	
E. Emergency Preparedness Task Force	N. Leikach, Chair	Emergency Preparedness Task Force Update	
IV. Other Business & FYI	M. Gavvani, President		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
V. Adjournment	M. Gavgani, President	<p><b>A. The Public Meeting was adjourned.</b></p> <p><b>B. M. Gavgani convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications.</b></p> <p><b>C. The Closed Public Session was adjourned. Immediately thereafter, M. Gavgani convened an Administrative Session for purposes of discussing confidential disciplinary cases.</b></p> <p><b>D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session.</b></p>	